Please sign in to follow a disease.
5,000-Patient registry aims to map the Long-Term course of lupus nephritis
NCT ID NCT03001973
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers in China are building a registry of people diagnosed with lupus nephritis, a kidney complication of lupus. The study plans to enroll 5,000 patients from participating hospitals and follow them with yearly check-ins. By collecting baseline and follow-up information, the team aims to understand long-term outcomes such as kidney failure, dialysis, and death. No experimental treatment is given; the goal is to gather real-world data on how the disease and its care unfold over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the registry succeeds, it could give doctors a clearer picture of how lupus nephritis progresses over years and which patients face the highest risks, guiding future treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial, so it cannot prove that any therapy works. Results depend on accurate record-keeping and long-term follow-up, and findings from Chinese hospitals may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2013
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Lupus nephritis patients
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who diagnosis as lupus nephritis Exclusion Criteria: * No
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lupus nephritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test catch lupus flares earlier?
- Can a single CAR-T infusion reset the immune system and stop lupus kidney damage?
- Blood markers may foretell kidney trouble in lupus
- Can bone marrow stem cells calm lupus kidney flares?
- Can a targeted antibody boost kidney remission in lupus?
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?